Analysis of potential risks of Tepotinib (Tuodekang) in the treatment of metastatic non-small cell lung cancer

Tepotinib (Tepotinib) is a selective oral MET inhibitor, mainly targeting non-small cell lung cancer (NSCLC) with METexon14 skipping mutation (METex14 skipping) patients. With the popularization of molecular testing technology, more and more patients can identify the type of genetic mutation, thereby obtaining personalized treatment opportunities. Clinical research data shows that tepotinib exhibits significant efficacy in alleviating tumor progression and prolonging progression-free survival. However, any targeted drug has potential risks, so when using tepotinib to treat metastatic non-small cell lung cancer, the efficacy and possible adverse reactions need to be considered comprehensively.

According to clinical trials and real-world data, common adverse reactions of tepotinib include peripheral edema, nausea, diarrhea, decreased appetite, and fatigue. Peripheral edema is the most representative side effect, with a high incidence rate and may have an impact on quality of life. In addition, some patients may experience liver function abnormalities (such as elevated transaminases), gastrointestinal reactions, and mild to moderate respiratory symptoms. Risk factors include older age, patients with underlying diseases (such as heart and liver diseases), and patients combined with other treatment options, who are often more likely to experience drug-related adverse events.

In rare cases, tepotinib may cause more serious complications, such as interstitial pneumonia, severe liver injury, and rare hematologic abnormalities. If such adverse reactions cannot be recognized and treated in time, they may lead to treatment interruption or even life-threatening. Therefore, in clinical practice, it is recommended to closely monitor patients' liver function, lung function and electrolyte levels during medication, and to detect risks in a timely manner through regular imaging examinations and laboratory tests. Once patients develop obvious difficulty breathing, persistent jaundice, or severe edema, they should seek medical attention immediately and adjust or discontinue medications.

Despite certain potential risks, tepotinib still provides an important treatment option in patients with metastatic non-small cell lung cancer, especially for patients with MET mutations who lack effective treatments. Through reasonable dose management, individualized treatment plans, and regular follow-up, risks can be minimized and efficacy improved. At the same time, with the accumulation of clinical experience and the release of more research data, the balance between safety and efficacy of tepotinib is expected to be further optimized in the future, bringing longer survival benefits to patients.

Reference link:https://www.drugs.com